Fig. 2: Characterization of tumor microenvironment following Annexin A5 treatment.
From: Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
C57BL/6 mice (10 per group) were injected with 2 × 105 TC-1 cells/mouse subcutaneously on day 0. Mice were then treated intraperitoneally with 5 mg/kg Cisplatin on days 12 and 15, and/or intravenously with 200jig/mice of Annexin A5 proteins on days 13, 14, 16, and 17. PBS was used as control. On day 18, tumor tissues and serum of mice were harvested. a Schematic diagram. b Bar graphs depicting the abundance of CD11b+ F4/80+ macrophages and their M1/M2 distributions in the tumor tissue following flow cytometry analysis (n = 3). c Bar graphs depicting the presence of CD8+ T cells, CD4+ T cells, Treg cells, and MDSCs in the tumor tissue following flow cytometry analysis (n = 3). d Bar graphs depicting the expression of PD-L1 by CD45+ immune cells and CD45- tumor cells following flow cytometry analysis (n = 3). e Bar graphs depicting the levels of TNF-α, IL-10 and TGF-3 cytokines in the tumor tissue and serum of mice as measured by ELISA (n = 3). The error bars indicate mean ± SD. N.S. = not significant. For (b–e), P-values were analyzed by Student’s t test. The results are representative of one of three independent experiments. Source data are provided as a Source Data file.
